{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:34:04Z","timestamp":1783758844972,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AR066286"],"award-info":[{"award-number":["R21AR066286"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jid.2022.03.029","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:24:08Z","timestamp":1651181048000},"page":"2651-2659.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P.","family":"Werth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-6317","authenticated-orcid":false,"given":"Emily","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-4725","authenticated-orcid":false,"given":"Sandra M.","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-0972","authenticated-orcid":false,"given":"Jessica","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-476X","authenticated-orcid":false,"given":"Majid","family":"Zeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-4265","authenticated-orcid":false,"given":"Nithin","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-1602","authenticated-orcid":false,"given":"Joyce","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-7228","authenticated-orcid":false,"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-2850","authenticated-orcid":false,"given":"Muhammad M.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-4010","authenticated-orcid":false,"given":"Kirubel","family":"Gebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3081-4318","authenticated-orcid":false,"given":"Arvin S.","family":"Jadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4421-1147","authenticated-orcid":false,"given":"Josef Symon S.","family":"Concha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-6609","authenticated-orcid":false,"given":"Nancy","family":"Dgetluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-3930","authenticated-orcid":false,"given":"Scott","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-665X","authenticated-orcid":false,"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 10","key":"10.1016\/j.jid.2022.03.029_bib1","volume":"73","author":"Aggarwal","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2022.03.029_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archderm.141.7.855","article-title":"Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study","volume":"141","author":"Ang","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","article-title":"The systemic management of cutaneous dermatomyositis: results of a stepwise strategy","volume":"3","author":"Anyanwu","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the cutaneous dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/03009742.2015.1020863","article-title":"Association between cannabinoid receptor type 2 Q63R variant and oligo\/polyarticular juvenile idiopathic arthritis","volume":"44","author":"Bellini","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jid.2022.03.029_bib7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.bbadis.2007.03.002","article-title":"TRP channels as novel players in the pathogenesis and therapy of itch","volume":"1772","author":"B\u00edr\u00f3","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jid.2022.03.029_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.03.029_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.03.029_bib10","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1021\/jm00095a007","article-title":"Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities","volume":"35","author":"Burstein","year":"1992","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jid.2022.03.029_bib11","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.V92.10.3605","article-title":"Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation","volume":"92","author":"Carayon","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jid.2022.03.029_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaad.2017.10.022","article-title":"Cutaneous dermatomyositis disease course followed over time using the cutaneous dermatomyositis Disease Area and Severity Index","volume":"79","author":"Chansky","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib13","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jid.2020.12.032","article-title":"Myeloid dendritic cells are major producers of IFN-\u03b2 in dermatomyositis and may contribute to hydroxychloroquine refractoriness","volume":"141","author":"Chen","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/pgmj.2005.038455","article-title":"Treatment of inflammatory myopathies","volume":"82","author":"Cordeiro","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jid.2022.03.029_bib15","doi-asserted-by":"crossref","first-page":"e5844","DOI":"10.1371\/journal.pone.0005844","article-title":"Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis","volume":"4","author":"Deveaux","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2022.03.029_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.116.232561","article-title":"Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway","volume":"358","author":"Dhopeshwarkar","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jid.2022.03.029_bib17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/mol.114.094649","article-title":"CB2 cannabinoid receptors as a therapeutic target\u2014what does the future hold?","volume":"86","author":"Dhopeshwarkar","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib18","first-page":"89","article-title":"Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis","volume":"61","author":"Engel","year":"2010","journal-title":"J\u00a0Physiol Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","article-title":"The clinical features, diagnosis and classification of dermatomyositis","volume":"48\u201349","author":"Iaccarino","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jid.2022.03.029_bib23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2013.11.002","article-title":"Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS","volume":"287","author":"Kong","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jid.2022.03.029_bib26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s11481-013-9493-1","article-title":"Cannabinoids decrease the Th17 inflammatory autoimmune phenotype","volume":"8","author":"Kozela","year":"2013","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/89759","article-title":"Lipid mediator class switching during acute inflammation: signals in resolution","volume":"2","author":"Levy","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2022.03.029_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/mol.63.5.983","article-title":"Activation and binding of peroxisome proliferator-activated receptor \u03b3 by synthetic cannabinoid ajulemic acid","volume":"63","author":"Liu","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/jm00269a002","article-title":"Cannabinoids. Structure-activity studies related to 1, 2-dimethylheptyl derivatives","volume":"16","author":"Loev","year":"1973","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jid.2022.03.029_bib30","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.jid.2020.03.901","article-title":"885 Major producers of IFNg and CB2 receptor distribution in dermatomyositis","volume":"140","author":"Maddukuri","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13075-021-02665-x","article-title":"Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in\u00a0vivo effects of Lenabasum [published correction appears in Arthritis Res Ther 2022;24:69]","volume":"24","author":"Maddukuri","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2022.03.029_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jid.2022.03.029_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2022.03.029_bib34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1476-5381.2010.00769.x","article-title":"CB1 cannabinoid receptors promote oxidative\/nitrosative stress, inflammation and cell death in a murine nephropathy model","volume":"160","author":"Mukhopadhyay","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.jid.2022.03.029_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.03.029_bib37","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar3549","article-title":"Tumor necrosis factor \u03b1 release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients","volume":"14","author":"Nabatian","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2022.03.029_bib38","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/sj.jid.5700212","article-title":"Testing and reducing skindex-29 using Rasch analysis: Skindex-17","volume":"126","author":"Nijsten","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib39","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O'sullivan","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2022.03.029_bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00296-007-0489-0","article-title":"Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid","volume":"28","author":"Parker","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jid.2022.03.029_bib42","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jid.2021.02.748","article-title":"Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis","volume":"141","author":"Patel","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib43","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","article-title":"Emerging strategies for exploiting cannabinoid receptor agonists as medicines","volume":"156","author":"Pertwee","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib46","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","article-title":"Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-\u03b1, and type I interferons in dermatomyositis in\u00a0vitro","volume":"137","author":"Robinson","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib48","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib49","doi-asserted-by":"crossref","first-page":"e42259","DOI":"10.1371\/journal.pone.0042259","article-title":"Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease","volume":"7","author":"Rossi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2022.03.029_bib50","first-page":"574","article-title":"Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes","volume":"26","author":"Selvi","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jid.2022.03.029_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2022.03.029_bib52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2022.03.029_bib53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1189\/jlb.0205111","article-title":"Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders","volume":"78","author":"Sipe","year":"2005","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jid.2022.03.029_bib54","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","article-title":"Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects","volume":"20","author":"Sontheimer","year":"2002","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jid.2022.03.029_bib55","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2022.03.029_bib56","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.bmc.2014.04.062","article-title":"UltraPure ajulemic acid has improved CB2 selectivity with reduced CB1 activity","volume":"22","author":"Tepper","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jid.2022.03.029_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.15140","article-title":"The reliability of the cutaneous dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists","volume":"176","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib58","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1478-3231.2011.02496.x","article-title":"Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts","volume":"31","author":"Trebicka","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jid.2022.03.029_bib59","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2022.03.029_bib60","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.03.029_bib61","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","article-title":"Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid","volume":"65","author":"Zurier","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jid.2022.03.029_bib62","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1096\/fj.08-118323","article-title":"Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4","volume":"23","author":"Zurier","year":"2009","journal-title":"FASEB J"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22002950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22002950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:51:22Z","timestamp":1762206682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X22002950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0022202X22002950"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.03.029","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}